Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis

I M Gan, J T van Dissel, W H Beekhuis, W Swart, J C van Meurs, I M Gan, J T van Dissel, W H Beekhuis, W Swart, J C van Meurs

Abstract

Background/aims: To study the intravitreal antibiotic concentrations and the efficacy of an intravitreal dosing regimen to treat patients with postoperative bacterial endophthalmitis. This regimen, based on pharmacokinetic/pharmacodynamic considerations, relies on a repeat antibiotic injection of a lower dose than is generally used.

Methods: In consecutive patients with suspected postoperative endophthalmitis a vitreous biopsy for bacterial culture was taken before 0.2 mg vancomycin and 0.05 mg gentamicin were injected intravitreally. After 3 or 4 days a second biopsy was taken for bacteriological culture and to measure intravitreal vancomycin and gentamicin concentrations, followed by a repeat injection of 0.2 mg vancomycin.

Results: 17 patients entered the study. In 11 patients the initial bacterial culture was positive, predominantly coagulase negative staphylococci. All second vitreous biopsies were sterile. Intravitreal vancomycin levels varied between 2.6 and 18.0 microg/ml (mean 10.3 (SD 4.1) microg/ml) after 3 days and between 3.1 and 16.6 microg/ml (mean 7.5 (6.2) microg/ml) after 4 days which is well above the minimal inhibitory concentration for most micro-organisms. Concentrations of intravitreal gentamicin varied between 0.90 and 3.3 microg/ml (mean 1.6 (0.72) microg/ml) after 3 days and between 1.2 and 2.6 microg/ml (mean 1.9 (0.99) microg/ml) after 4 days.

Conclusion: This dosing regimen resulted both in adequate intravitreal vancomycin and gentamicin levels for over a week as well as in negative second cultures. This study also provides new information on intravitreal vancomycin and gentamicin concentration over time in patients with postoperative endophthalmitis.

Figures

Figure 1
Figure 1
Intravitreal vancomycin concentrations.
Figure 2
Figure 2
Intravitreal gentamicin concentrations.
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1723787/bin/bjo-medm.f1.jpg

References

    1. Ophthalmology. 1982 Sep;89(9):1055-66
    1. J Ocul Pharmacol Ther. 1998 Dec;14(6):555-63
    1. Arch Ophthalmol. 1986 Mar;104(3):367-71
    1. Ophthalmology. 1986 Jul;93(7):871-7
    1. Ophthalmology. 1986 Oct;93(10):1328-35
    1. Arch Ophthalmol. 1999 Aug;117(8):1023-7
    1. Arch Ophthalmol. 1999 Aug;117(8):1058-62
    1. Arch Ophthalmol. 1974 Jul;92(1):42-7
    1. Am J Ophthalmol. 1976 Oct;82(4):604-11
    1. Arch Ophthalmol. 1976 Dec;94(12):2078-81
    1. Am J Ophthalmol. 1981 Jul;92(1):59-62
    1. Surv Ophthalmol. 1982 Jan-Feb;26(4):204-6
    1. Arch Ophthalmol. 1987 Jun;105(6):831-7
    1. Invest Ophthalmol Vis Sci. 1989 Jun;30(6):1055-61
    1. Arch Ophthalmol. 1991 Feb;109(2):175-6
    1. Ophthalmology. 1991 Feb;98(2):227-38
    1. J Toxicol Clin Toxicol. 1992;30(2):285-94
    1. Arch Ophthalmol. 1994 Jan;112(1):48-53
    1. Am J Ophthalmol. 1995 Jun;119(6):774-8
    1. Retina. 1995;15(5):428-32
    1. J Toxicol Clin Toxicol. 1996;34(1):83-6
    1. Am J Ophthalmol. 1996 Jul;122(1):1-17
    1. Klin Monbl Augenheilkd. 1996 May;208(5):358-9
    1. Aust N Z J Ophthalmol. 1996 May;24(2):143-6
    1. Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2
    1. Pediatr Nephrol. 1998 Jan;12(1):63-4
    1. Ann Intern Med. 1984 Jul;101(1):92-104

Source: PubMed

3
Suscribir